Moteur de recherche d’entreprises européennes
UK funding (409 180 £) : Characterisation of a novel series of small molecule androgen receptor modulators in prostate cancer Ukri01/01/2009 UK Research and Innovation, Royaume Uni
Vue d’ensemble
Texte
Characterisation of a novel series of small molecule androgen receptor modulators in prostate cancer
| Abstract | Prostate cancer causes approximately 10,000 deaths in the UK each year. Current treatments attempt to prevent the action of the androgen receptor, a protein that drives prostate cancer growth. Unfortunately, these treatments are not effective in the long-term and the generation of disease that no longer responds to this therapy, termed hormone-refractory prostate cancer (HRPC), is common and often fatal. Therefore, the key goal for researchers is to develop new drugs that can be used to treat this disease. The androgen receptor remains an important driving force in the development of HRPC and therefore the generation of new agents that can permanently block it?s function are necessary to effectively treat the disease. This project will study the effect of a new panel of drugs that can inactivate the androgen receptor in several model systems of HRPC. These studies will provide important information regarding the effect of these agents on androgen receptor action and growth of prostate cancer cells. Ultimately, this work will be important for determining the effectiveness of these drugs as future therapies for prostate cancer treatment. |
| Category | Research Grant |
| Reference | RCS G0800889 |
| Status | Closed |
| Funded period start | 01/01/2009 |
| Funded period end | 31/12/2011 |
| Funded value | £409 180,00 |
| Source | https://gtr.ukri.org/projects?ref=G0800889 |
Participating Organisations
| Newcastle University | |
| Astex Pharmaceuticals | |
| AstraZeneca plc | |
| Tokai Pharmaceuticals Inc |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : University OF Newcastle Upon Tyne CHARITY, Newcastle upon Tyne, Royaume Uni.
Les visualisations de "Newcastle University - UK funding (409 180 £) : Characterisation of a novel series of small molecule androgen receptor modulators in prostate cancer"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
